Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06322238 · ClinicalTrials.gov registry record · Phase 2
Pharmacogenetic Panel to Prevent Adverse Drug Reactions in Daily Primary Care Practice:
A Phase 2 study of Pharmacogenomic Drug Interaction and Drug Metabolism, Poor, CYP2D6-Related, sponsored by Mayo Clinic.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 66
- Enrollment target
- 1
- Study location
NCT06322238: Recruiting Phase 2 study of Pharmacogenomic Drug Interaction and Drug Metabolism, Poor, CYP2D6-Related, sponsored by Mayo Clinic.
NCT06322238 is a Phase 2 study of Pharmacogenomic Drug Interaction and Drug Metabolism, Poor, CYP2D6-Related that is actively recruiting participants, run by Mayo Clinic. The registered enrollment target is 66 participants, below the 735-participant average among 4 other Pharmacogenomic Drug Interaction trials with a reported enrollment target (91% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06322238, a Phase 2 study of Pharmacogenomic Drug Interaction and Drug Metabolism, Poor, CYP2D6-Related, is actively recruiting participants, sponsored by Mayo Clinic.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 66 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to determine whether the implementation of pre-emptive pharmacogenomic (PGx) testing of a panel of clinically relevant PGx markers, to guide the dose and drug selection for 39 commonly prescribed drugs, will result in an overall reduction in the number of clinically relevant drug-genotype associated ADRs which are causally related to the initial drug of inclusion (referred to as 'index drug').
Primary Outcome
The count of participants who experience any of the following ADR's: muscle aches, falling, tripping, fainting, palpations, emotional changes, or physical changes
Conditions Studied
Interventions
- DIAGNOSTIC_TEST PGx panel test
Study Locations (1)
Minnesota
- Mayo Clinic - Rochester
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 66 participants |
| Start Date | 2024-12-01 |
| Est. Completion | 2027-04 |
| Phase | Phase 2 |
What NCT06322238 shows while recruiting
NCT06322238 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 66 participants, a relatively small participant target, below the 735-participant average among 4 other Pharmacogenomic Drug Interaction trials with a reported enrollment target (91% lower).
The record links to 5 conditions, with Pharmacogenomic Drug Interaction appearing as the primary indexed condition, and to 1 intervention - of which PGx panel test is the first listed.
NCT06322238 reports a single indexed study location in Minnesota.
Frequently Asked Questions
What is clinical trial NCT06322238 about?
NCT06322238 is a clinical study titled "Pharmacogenetic Panel to Prevent Adverse Drug Reactions in Daily Primary Care Practice:". The purpose of this study is to determine whether the implementation of pre-emptive pharmacogenomic (PGx) testing of a panel of clinically relevant PGx markers, to guide the dose and drug selection for 39 commonly prescribed drugs, will result in an overall reduction in the number of clinically rele...
What is the current status of trial NCT06322238?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 66 participants. The study started on 2024-12-01. Estimated completion is 2027-04.
What conditions does trial NCT06322238 study?
This clinical trial studies the following conditions: Pharmacogenomic Drug Interaction, Drug Metabolism, Poor, CYP2D6-Related, Drug Metabolism, Poor, CYP2C19-Related, Side Effect of Drug, Ineffective Drug Action.
What interventions are being tested in trial NCT06322238?
The interventions under investigation include: PGx panel test (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT06322238?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06322238 being conducted?
This trial has 1 study location across Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Pharmacogenomic Drug Interaction
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Oral Contraceptive Pill (OCP) Pharmacogenomics
RECRUITING · Phase 4
-
The Geriatric Emergency Department Pharmacologic Harm Prevention Project
RECRUITING · NA
-
Pharmacogenomic Contributions to Trihexyphenidyl Biotransformation and Response in Children With Dystonic Cerebral Palsy
RECRUITING · Phase 1
-
Trial of Precision Medicine in Emergency Departments
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02584244 · 66 participants · Phase 1
Feasibility of the LUM Imaging System for Detection of Gastrointestinal Cancers
- NCT03067051 · 66 participants · Phase 1
Clinical Study to Assess the Safety and Efficacy of the SpectraCure P18 System
- NCT03754725 · 66 participants · Phase 1
Ferritin and Iron Burden in SAH sIRB
- NCT03875378 · 66 participants · Phase 2
Transdermal Estrogen in Women With Anorexia Nervosa
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI